Bleeding-Related Hospitalizations Among Direct Oral Anticoagulant Users and Nonusers in Medicare Fee-For-Service: Variation in Prevalence, Burden, and Characteristics

IF 4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Carol M. Bazell, Maggie N. Alston, Latha G. Ganti, Raymond C. Chang, H. Andrew Wilsey, Stephanie A. Leary, Winston C. Fopalan, Christopher W. Baugh
{"title":"Bleeding-Related Hospitalizations Among Direct Oral Anticoagulant Users and Nonusers in Medicare Fee-For-Service: Variation in Prevalence, Burden, and Characteristics","authors":"Carol M. Bazell,&nbsp;Maggie N. Alston,&nbsp;Latha G. Ganti,&nbsp;Raymond C. Chang,&nbsp;H. Andrew Wilsey,&nbsp;Stephanie A. Leary,&nbsp;Winston C. Fopalan,&nbsp;Christopher W. Baugh","doi":"10.1007/s12325-025-03287-4","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Bleeding-related hospitalizations represent a major burden for patients and the US healthcare system. Anticoagulant therapies pose a greater risk for bleeding, especially among the older Medicare population. Direct oral anticoagulants (DOACs) have become the most common type of oral anticoagulant used in Medicare due to their clinical advantages. This descriptive study examines the burden of bleeding-related hospitalizations among DOAC users and nonusers (with no evidence of anticoagulant or antiplatelet use) in Medicare fee-for-service (FFS).</p><h3>Methods</h3><p>This was an observational retrospective cohort study of bleeding-related hospitalizations in Medicare FFS using the 2020–2022 Medicare 100% Research Identifiable Files. We used 2020–2021 pharmacy claims to classify beneficiaries into DOAC user and nonuser cohorts and 2021–2022 healthcare administrative claims to identify demographics, bleeding-related hospitalization characteristics, and outcomes.</p><h3>Results</h3><p>Of 18.4 million Medicare FFS beneficiaries who met the study’s enrollment requirements, 9.3% were assigned to the DOAC user cohort, 81.5% were assigned to the nonuser cohort, and 9.1% were excluded (non-DOAC anticoagulant-only or prescription antiplatelet-only users). The bleeding-related hospitalization rate was four times higher in the DOAC user cohort compared to the nonuser cohort (27.5 and 6.7 per 1000 beneficiaries, respectively). Gastrointestinal bleeding was the most common bleed type leading to hospitalization in both DOAC user and nonuser cohorts (64.6% and 55.4%, respectively), followed by intracerebral hemorrhage (21.3% and 34.5%, respectively), and other types of bleeding (14.2% and 10.1%, respectively). Characteristics and outcomes were similar between cohorts, with variation largely related to bleeding type.</p><h3>Conclusion</h3><p>This study demonstrated variations in use of DOACs and characteristics of bleeding-related hospitalizations and identified higher rates of bleeding-related hospitalizations among DOAC users compared to nonusers. Hospitalization characteristics and outcomes differed by bleeding type. These findings highlight the Medicare FFS burden of bleeding-related hospitalizations and opportunities for the improved detection and management of bleeding, particularly among DOAC users.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 10","pages":"4916 - 4932"},"PeriodicalIF":4.0000,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03287-4.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-025-03287-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Bleeding-related hospitalizations represent a major burden for patients and the US healthcare system. Anticoagulant therapies pose a greater risk for bleeding, especially among the older Medicare population. Direct oral anticoagulants (DOACs) have become the most common type of oral anticoagulant used in Medicare due to their clinical advantages. This descriptive study examines the burden of bleeding-related hospitalizations among DOAC users and nonusers (with no evidence of anticoagulant or antiplatelet use) in Medicare fee-for-service (FFS).

Methods

This was an observational retrospective cohort study of bleeding-related hospitalizations in Medicare FFS using the 2020–2022 Medicare 100% Research Identifiable Files. We used 2020–2021 pharmacy claims to classify beneficiaries into DOAC user and nonuser cohorts and 2021–2022 healthcare administrative claims to identify demographics, bleeding-related hospitalization characteristics, and outcomes.

Results

Of 18.4 million Medicare FFS beneficiaries who met the study’s enrollment requirements, 9.3% were assigned to the DOAC user cohort, 81.5% were assigned to the nonuser cohort, and 9.1% were excluded (non-DOAC anticoagulant-only or prescription antiplatelet-only users). The bleeding-related hospitalization rate was four times higher in the DOAC user cohort compared to the nonuser cohort (27.5 and 6.7 per 1000 beneficiaries, respectively). Gastrointestinal bleeding was the most common bleed type leading to hospitalization in both DOAC user and nonuser cohorts (64.6% and 55.4%, respectively), followed by intracerebral hemorrhage (21.3% and 34.5%, respectively), and other types of bleeding (14.2% and 10.1%, respectively). Characteristics and outcomes were similar between cohorts, with variation largely related to bleeding type.

Conclusion

This study demonstrated variations in use of DOACs and characteristics of bleeding-related hospitalizations and identified higher rates of bleeding-related hospitalizations among DOAC users compared to nonusers. Hospitalization characteristics and outcomes differed by bleeding type. These findings highlight the Medicare FFS burden of bleeding-related hospitalizations and opportunities for the improved detection and management of bleeding, particularly among DOAC users.

直接口服抗凝剂使用者和非医疗服务收费使用者的出血相关住院:患病率、负担和特征的变化
导言:与出血相关的住院治疗是患者和美国医疗保健系统的主要负担。抗凝治疗有更大的出血风险,特别是在老年医保人群中。直接口服抗凝剂(DOACs)由于其临床优势已成为医疗保险中最常用的口服抗凝剂。本描述性研究考察了DOAC使用者和非使用者(无抗凝或抗血小板使用证据)在医疗保险按服务收费(FFS)中的出血相关住院负担。方法:这是一项观察性回顾性队列研究,使用2020-2022年医疗保险100%研究可识别文件对医疗保险FFS中出血相关住院进行研究。我们使用2020-2021年药房索赔将受益人分为DOAC用户和非用户队列,并使用2021-2022年医疗行政索赔来确定人口统计学、出血相关住院特征和结果。结果:在满足研究入组要求的1,840万联邦医疗保险FFS受益人中,9.3%被分配到DOAC使用者队列,81.5%被分配到非DOAC使用者队列,9.1%被排除(非DOAC抗凝剂或处方抗血小板药物的纯使用者)。与未使用DOAC的人群相比,使用DOAC的人群与出血相关的住院率高出4倍(分别为每1000名受益人27.5人和6.7人)。胃肠道出血是DOAC使用者和非使用者中最常见的导致住院的出血类型(分别为64.6%和55.4%),其次是脑出血(分别为21.3%和34.5%)和其他类型出血(分别为14.2%和10.1%)。队列之间的特征和结果相似,差异主要与出血类型有关。结论:本研究证明了DOAC的使用和出血相关住院特征的差异,并确定了DOAC使用者与非使用者相比,出血相关住院率更高。不同出血类型的住院特点和结局不同。这些发现突出了联邦医疗保险FFS出血相关住院的负担,以及改善出血检测和管理的机会,特别是在DOAC使用者中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Therapy
Advances in Therapy 医学-药学
CiteScore
7.20
自引率
2.60%
发文量
353
审稿时长
6-12 weeks
期刊介绍: Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信